Loading...
•
Jun 30, 2023
Delcath Q2 2023 Earnings Report
Reported second quarter 2023 results and provided a business update.
Key Takeaways
Delcath Systems reported total revenue of $0.5 million for the second quarter ended June 30, 2023, compared to $0.8 million for the prior year period. The company's research and development expenses were $3.6 million, compared to $5.6 million in the prior year quarter. Selling, general and administrative expenses for the quarter increased to $4.8 million, compared to $4.5 million in the prior year quarter.
Continued communication with the FDA regarding the HEPZATO KIT™ NDA resubmission, with an anticipated PDUFA date of August 14, 2023.
Stockholders approved the potential issuance of common stock upon conversion of preferred stock from a private placement, generating $25 million on closing with potential for up to an additional $60 million upon warrant exercises and revenue milestones.
Hired Vojislav Vukovic, MD, PhD as Chief Medical Officer, Sandra Pennell as Senior Vice President of Finance, and Zac MacLean as Director of Sales and Strategy.
Continued to treat patients at 3 Expanded Access Program sites.
Forward Guidance
The Company has been preparing for the commercialization of HEPZATO KIT, if approved.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...